A5007869221- Circular RNAs in diseases
- MicroRNA in disease regulation
- Glutathione Transferases and Polymorphisms
- Heat shock proteins research
- Pancreatic and Hepatic Oncology Research
- Prostate Cancer Treatment and Research
- Epigenetics and DNA Methylation
- Ubiquitin and proteasome pathways
- Cancer, Hypoxia, and Metabolism
- Cancer Research and Treatments
- Kruppel-like factors research
- Extracellular vesicles in disease
- Angiogenesis and VEGF in Cancer
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Biological Research and Disease Studies
- Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Biochemical and Molecular Research
- ATP Synthase and ATPases Research
- Hedgehog Signaling Pathway Studies
- Genomics, phytochemicals, and oxidative stress
- Amino Acid Enzymes and Metabolism
- Cancer Genomics and Diagnostics
- Immune cells in cancer
National Center on Addiction and Substance Abuse at Columbia University
2025
Columbia University
2023-2024
Columbia University Irving Medical Center
2021-2024
Cornell University
2017-2021
Weill Cornell Medicine
2021
New York University
2020
Abstract Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by mutations 1,2 . RMC-7977 is highly selective inhibitor active GTP-bound forms KRAS, HRAS and NRAS, affinity for both mutant wild-type variants 3 More than 90% cases pancreatic ductal adenocarcinoma (PDAC) activating in KRAS 4 Here we assessed therapeutic comprehensive range PDAC models. We observed broad pronounced anti-tumour activity across models...
Hsp90 is a molecular chaperone that protects proteins, including oncogenic signaling complexes, from proteolytic degradation. PU-H71 next-generation inhibitor preferentially targets the functionally distinct pool of present in tumor cells. Tumors are driven by MYC oncoprotein may be particularly sensitive to due essential role epichaperome, which maintains malignant phenotype setting MYC. Burkitt lymphoma (BL) an aggressive B-cell characterized dysregulation. In this study, we evaluated as...
Abstract Sensitivity to therapeutic agents is impacted both by genetic heterogeneity between patients or among clones within a tumor and of epigenetic cell states. Prior work demonstrates that human pancreatic tumors comprise malignant cells in mixture multiple states with distinct dependencies, leading reservoir chemoresistance across the tumor; targeting just one two insufficient achieve durable responses. One approach overcome this challenge identify efficacy against However, absence...
Abstract The sparse vascularity of pancreatic ductal adenocarcinoma (PDAC) presents a mystery: What prevents this aggressive malignancy from undergoing neoangiogenesis to counteract hypoxia and better support growth? An incidental finding prior work on paracrine communication between malignant PDAC cells fibroblasts revealed that inhibition the Hedgehog (HH) pathway partially relieved angiosuppression, increasing tumor through unknown mechanisms. Initial efforts study phenotype were hindered...
Summary Broad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by mutations. However, impact inhibiting functions in normal tissues is not known. RMC-7977 highly selective inhibitor active (GTP-bound) forms KRAS, HRAS, and NRAS, with affinity for both mutant wild type (WT) variants. As >90% pancreatic ductal adenocarcinoma (PDAC) cases activating mutations KRAS , we assessed therapeutic comprehensive range PDAC...
Abstract The sparse vascularity of Pancreatic Ductal Adenocarcinoma (PDAC) presents a mystery: what prevents this aggressive malignancy from undergoing neoangiogenesis to counteract hypoxia and better support growth? An incidental finding prior work on paracrine communication between malignant PDAC cells fibroblasts revealed that inhibition the Hedgehog (HH) pathway partially relieved angiosuppression, increasing tumor through unknown mechanisms. Initial efforts study phenotype were hindered...
Abstract Sensitivity to therapeutic agents is impacted both by genetic heterogeneity between patients or among clones within a tumor and of epigenetic cell states. Prior work demonstrates that human pancreatic tumors comprise malignant cells in mixture multiple states with distinct dependencies, leading reservoir chemoresistance across the tumor; targeting just one two insufficient achieve durable responses. One approach overcome this challenge identify efficacy against However, absence...
Abstract The advent of Ras inhibitors has revolutionized the treatment paradigm for pancreatic ductal adenocarcinoma (PDAC). However, preclinical models and early clinical results have shown that inhibitor monotherapy is insufficient to produce durable anti-tumor responses. Thus, there a great need design rational combination therapies can increase effect inhibitors. Oncogenic K-Ras known drive profoundly immunosuppressive tumor immune microenvironment (TIME) characteristic PDAC tumors....
<p>WNT Distribution and Expression of Downstream Targets.</p>
<p>Explant cellular populations throughout culture.</p>
<p>Overview of single cell regulatory network analysis.</p>
<p>Single cell analysis of paracrine cascades in KPC PDAC.</p>
<p>Single cell analysis of paracrine cascades in KPC PDAC.</p>
<p>Explant cellular populations throughout culture.</p>
<div>Abstract<p>The sparse vascularity of pancreatic ductal adenocarcinoma (PDAC) presents a mystery: What prevents this aggressive malignancy from undergoing neoangiogenesis to counteract hypoxia and better support growth? An incidental finding prior work on paracrine communication between malignant PDAC cells fibroblasts revealed that inhibition the Hedgehog (HH) pathway partially relieved angiosuppression, increasing tumor through unknown mechanisms. Initial efforts study...
<div>Abstract<p>The sparse vascularity of pancreatic ductal adenocarcinoma (PDAC) presents a mystery: What prevents this aggressive malignancy from undergoing neoangiogenesis to counteract hypoxia and better support growth? An incidental finding prior work on paracrine communication between malignant PDAC cells fibroblasts revealed that inhibition the Hedgehog (HH) pathway partially relieved angiosuppression, increasing tumor through unknown mechanisms. Initial efforts study...
<p>WNT Distribution and Expression of Downstream Targets.</p>
<p>IPI-926 treatment alters cellular composition in the tumor microenvironment.</p>